There were 2,050 press releases posted in the last 24 hours and 433,633 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image